Most Read Articles
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 6 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 3 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.
Yesterday
Monotherapy with tocilizumab (TCZ) shows good tolerability profile and results in remission in most patients with polymyalgia rheumatica (PMR) despite the absence of glucocorticoids, according to the 2-year results of a single-centre, open‐label pilot study.

Ageing men on TRT suffer from greater cardiovascular risk

21 Oct 2019
Looking into 2018, Singapore has a few plans in mind to improve healthcare for the public, especially the elderly.

Testosterone replacement therapy (TRT) may come with an increased risk of cardiovascular events in ageing men with low testosterone levels, a new study has found.

Accessing the UK Clinical Practice Research Datalink, researchers investigated the role of TRT on clinical outcomes in 15,041 men (mean age, 60.4±9.6 years) with low testosterone levels and no evidence of hypogonadotropic or testicular disease. The primary outcome was a composite between ischaemic stroke/transient ischaemic attacks and myocardial infarction.

TRT was prescribed to 4,485 men on at least one occasion, most of whom used testosterone gels/creams (56.8 percent); 33.6 percent received TRT via injections.

Over 71,541 person-years of follow-up, 850 cases of the composite outcome were reported, resulting in a crude incidence rate of 1.19 (95 percent CI, 1.11–1.27) per 100 persons per year. Current TRT use increased the risk of the primary outcome by 21 percent (hazard ratio [HR], 1.21, 1.00–1.46).

In absolute terms, TRT use would account for an adjusted risk difference of 2.4 events per 1,000 persons per year.

Stratified analysis found that this risk peaked in the first 6 months to 2 years of continuous TRT use (HR, 1.35, 1.01–1.79) but tapered thereafter. The effect was also strongest among those aged 45–59 years (HR, 1.44, 1.07–1.92).

Notably, current use significantly reduced the risk of all-cause mortality (HR, 0.64, 0.52–0.78) relative to nonuse of TRT, while past use had the opposite effect (HR, 1.72, 1.21–2.45).

The principal results were robust to sensitivity analyses and remained consistent even after disaggregation according to TRT formulation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 6 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 3 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.
Yesterday
Monotherapy with tocilizumab (TCZ) shows good tolerability profile and results in remission in most patients with polymyalgia rheumatica (PMR) despite the absence of glucocorticoids, according to the 2-year results of a single-centre, open‐label pilot study.